A recent study has revealed that over 60% of patients with Crohn’s disease experienced sustained remission when treated with subcutaneous biosimilar CTP13. The study, published in a renowned gastroenterology journal, highlights the potential of this biosimilar therapy in managing Crohn’s disease effectively. The researchers conducted a clinical trial involving a significant number of patients diagnosed with moderate to severe Crohn’s disease. They administered subcutaneous injections of CTP13, a biosimilar of a widely used biologic drug, to the participants. After a specified treatment period, they observed that more than 60% of the patients achieved remission and sustained it throughout the study. This finding is significant as it provides evidence for the efficacy and safety of CTP13 in treating Crohn’s disease.

Read More